Comparing Efficacy of Microwave Vs Embolization Treatment for Adenomyosis
NCT ID: NCT04209127
Last Updated: 2024-11-20
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
70 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-09-16
Study Completion Date
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Single blinded randomized controlled study of symptom improvement after uterine artery embolization (UAE) versus ultrasound guided percutaneous/transvaginal microwave ablation, evaluated by validated questionnaires.
Adenomyosis is a benign condition causing pain and bleeding disorders in many women. Hysterectomy has historically been the golden standard for treatment as well as (postoperatively) diagnosis of the disease. In accordance with refined diagnostic tools such as ultrasound and/or MRI, minimally invasive treatments for adenomyosis are being explored.
We plan to compare two minimally invasive techniques: embolization of the uterine artery (a commonly used procedure) and microwave ablation of adenomyotic tissue (previously only in clinical use in China).
Adenomyosis is a benign condition causing pain and bleeding disorders in many women. Hysterectomy has historically been the golden standard for treatment as well as (postoperatively) diagnosis of the disease. In accordance with refined diagnostic tools such as ultrasound and/or MRI, minimally invasive treatments for adenomyosis are being explored.
We plan to compare two minimally invasive techniques: embolization of the uterine artery (a commonly used procedure) and microwave ablation of adenomyotic tissue (previously only in clinical use in China).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Uterine Artery Embolization (UAE) in Management of Symptomatic Uterine Adenomyosis
NCT06652945
Uterine Adenomyosis
NOT_YET_RECRUITING
NA
Emmy Trial: Uterine Artery Embolization (UAE) Versus Hysterectomy for Uterine Fibroids
NCT00100191
Menorrhagia
Leiomyoma
Uterine Neoplasms
COMPLETED
PHASE3
Role of Uterine Artery Embolization in Adenomyosis
NCT05597644
Adenomyosis
NOT_YET_RECRUITING
EARLY_PHASE1
Uterine Artery Embolization for Symptomatic Fibroids
NCT00354471
Uterine Fibroids
Menorrhagia
Adenomyosis
COMPLETED
Adenomyosis and Pregnancy Outcomes in Women Undergoing Assisted Reproductive Technology Treatment
NCT05418140
Adenomyosis
Infertility
ART
+2 more
ACTIVE_NOT_RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Single blinded randomized controlled study of symptom improvement after uterine artery embolization (UAE) versus ultrasound guided percutaneous/transvaginal microwave ablation, evaluated by validated questionnaires.
Background
Adenomyosis is a benign gynecological condition, where endometrial glands and stroma invades the myometrial walls of the uterus. The disease is thought to be estrogen-dependent, but the etiology, as well as the prevalence, is currently unknown. Known risk-factors are previous uterine surgery and parity, although the disease has been found also in nulligravida with no previous uterine trauma. Adenomyosis can cause severe dysmenorrhea, menorrhagia, chronic pelvic pain and infertility. Historically diagnosis has been made post hysterectomy by pathologists, however with transvaginal ultrasound (TVUS) as well as MRI the condition is now possible to identify with non-invasive methods.
Hysterectomy has previously been seen as the golden standard treatment for adenomyosis, but may cause long-term side effects such as genitovaginal prolapse. It also carries a substantial risk of short term complications such as infections and organ damage.
Symptomatic treatment such as the levonogestrel intrauterine system (LNG-IUS) can be effective, however there is a risk of expulsion and irregular bleedings.
In recent years, increasing attention has been paid to the study of minimally invasive or non-invasive therapies with uterine preservation such as uterine arterial embolization (UAE), radiofrequency (RF), microwave treatment and high intensity focused ultrasound (HIFU). A randomized controlled study is ongoing, comparing UAE and hysterectomy. RF ablation often requires the aid of a laparoscopic procedure, which is invasive. HIFU is currently only described in small cohorts and case-reports. Ultrasound or computer tomography guided percutaneous microwave thermal ablation is minimally invasive, has low time requirements, is easy to perform, and has been broadly used for the treatment of solid tumours in organs other than the uterus with favourable effects.
Microwave ablation of adenomyosis has been performed in China. The effect and acceptability has been high. The research team in this study has been to China to study the treatment. We have visited the clinic and studied the procedure as well as talked to patients pre- and post operatively . The equipment at Danderyd Hospital has the same output effects as the equipment in China. Danderyd Hospital has approved the method for use in uterine myomas. However, no randomized comparative study of other minimally invasive methods has been performed.
This study aims to compare the effectiveness, feasibility and acceptability of percutaneous CT- or ultrasound guided microwave ablation and uterine artery embolization for the treatment of adenomyosis in a randomized single blind study.
Recruitment and Randomization
Women fulfilling inclusion criteria and without exclusion criteria will be identified at the outpatient clinic of Danderyd Hospital. Advertisement may be placed in local newspapers or on social media (Facebook and Instagram) and relevant webpages or in gynecological clinics.
Women will be randomized after having been informed orally and in written and after having signed informed consent and after fulfilling inclusion and exclusion criteria after MRI-examination. Randomization will be in random permuted blocks of 6 at a ratio of 1:1. The randomization will be according to a computer generated randomization sequence. After patients have signed informed consent and fulfill inclusion without exclusion criteria after the initial magnetic resonance imaging they will be allocated to an intervention by consecutive opening of sealed opaque envelopes containing the randomization code.
Blinding
Patients and investigators will not be blinded. The MRI will be performed and evaluated by a blinded radiologist.
Method
Pre randomization evaluation After having signed informed consent but before randomization patients will undergo MRI of the uterus. Patients with endometriosis or a clinically significant presence of uterine fibroids (myomas\>3cm) will be excluded.
All women included in the study after MRI examination will fill in a PBAC evaluation during the menses preceding treatment. Women will fill a VNRS for maximal pain during 1 month prior to treatment. In addition a full blood panel will be evaluated.
As for uterine artery embolization no pathologist report will be performed before any treatment.
Microwave ablation Microwave ablation will be performed percutaneously or vaginally using a Covidien Emprint microwave ablation system with a 30-80 Watts effect in 14-16 gauge needle with a ceramic tip using computer tomography with fusion technique or ultrasound for adenomyosis imaging and needle guidance. After identification of the needle path with CT or peroperative ultrasound a small skin incision using a scalpel will made for the needle entry in the case of percutaneous treatment. No incision will be made if treatment is given vaginally. When needed to optimize the needle path in order not to damage adjacent organs, artificial ascites (approx 500mL Ringer-acetate) will be created using a thin syringe through the abdominal wall. The ablation zone of a 70W needle is estimated to be 4x3x3 cm after 300s or 5x4x4 cm after 600s. Patients will be given intravenous anesthesia with spontaneous breathing or general anesthesia during treatment to minimize movement during ablation.
Uterine artery embolization Embolization will be performed in conscious women with an epidural catheter or patient controlled analgesia for pain relief. A catheter will be inserted in the femoral artery to access the uterine artery during x-ray monitoring and during administration of contrast to visualize the adenomyotic tissue and its supporting arterial supply. When the supporting arterial branch has been identified polyvinyl alcohol particles are released into the bloodstream. These particles cause a thrombosis in the vessel.
Evaluation post treatment Women will estimate VNRS maximum postoperative pain day of surgery and the following 7 days. In addition, they will note how many days passed before all pain subsided, use of pain medication will be noted and period until resuming normal daily activities. The period of hospitalization will be noted.
Menstrual blood loss (PBAC) will be noted the first menstruation, menstruation number 3 and 5 post treatment. PBAC is a validated instrument for menstrual blood loss quantification. UFS-QOL is a validated instrument for women with uterine fibroids, but is commonly used also in trials regarding adenomyosis, and will be evaluated 6 months post treatment.
Follow-up visits will be after 1-2 menstruation at approximately 2 months and at 6 months post-treatment.
At follow up visit 2 months (+/-2 weeks) and 6 months (+/-2 weeks) post treatment acceptability will be assessed as overall satisfaction of treatment on a scale from 1-7 and if the woman would recommend the treatment to a friend. At the follow up visit at 6 months hemoglobin, cancer antigen 125 (CA-125), Anti-Müllerian Hormone (AMH), and prolactine (PRL) will be measured. AMH estimates the effect of the treatment on the ovarian reserve. CA-125 and PRL have been used to evaluate pathophysiological changes in adenomyosis. These will be compared to levels taken on the day of the operative procedure. A uterine biopsy will also be performed.
A new MRI scan will be performed 6 months post treatment (+/-21 days). Women will then be asked to participate in a long-term follow up (\>12 months) with evaluation of recurrence of symptoms, with clinical controls (gynecological exams and TVUS) and using PBAC and UFS-QOL yearly until retraction of consent.
Continuation of the study:
During our analysis of the initial pilot study, we noticed significant alleviation of symptoms in both treatment groups, however no significant difference between the groups (MWA vs UAE).
We however noted a significant better postoperative outcome in the MWA group:
hospitalization, return to ADL and need of analgesics postoperatively were all strongly in favor of MWA.
Also, the international research on MWA and fertility wish has proceeded during our initial study period, suggesting no significant higher risk for adverse oucomes in pregnancies after MWA.
These altered conditions made us apply for a continuation of the study to the Regional Ethical Review Board of Stockholm, with the following design:
* Prospective Interventional study of MWA treatment for symptomatic adenomyosis, n=50
* All patients receive MWA treatment and follow-up after 6 months
* Inclusion criterias remain unchanged, except for MRI no longer needed for diagnostics
* Fertility wish, cocurrent myomas and/or endometriosis no longer an exlusion criteria
Primary and secondary outcomes remain unchanged. Due to reasons listed above, we have now expanded the study period until June 2026.
Clinical significance
Adenomyosis is a benign condition but have a significant impact on the lives of women, and the condition is not well studied. Reports have suggested adenomyosis in approximately 40% of patients undergoing hysterectomy. Women with adenomyosis are much more likely to report on symptoms as dysmenhorrea, heavy menstrual bleeding, infertility and chronic pelvic pain. As hysterectomy is a highly invasive procedure with costs for women in terms of absence from work and short and long term complications, finding new minimally invasive and uterine-sparing treatments would be beneficial for affected women.
Background
Adenomyosis is a benign gynecological condition, where endometrial glands and stroma invades the myometrial walls of the uterus. The disease is thought to be estrogen-dependent, but the etiology, as well as the prevalence, is currently unknown. Known risk-factors are previous uterine surgery and parity, although the disease has been found also in nulligravida with no previous uterine trauma. Adenomyosis can cause severe dysmenorrhea, menorrhagia, chronic pelvic pain and infertility. Historically diagnosis has been made post hysterectomy by pathologists, however with transvaginal ultrasound (TVUS) as well as MRI the condition is now possible to identify with non-invasive methods.
Hysterectomy has previously been seen as the golden standard treatment for adenomyosis, but may cause long-term side effects such as genitovaginal prolapse. It also carries a substantial risk of short term complications such as infections and organ damage.
Symptomatic treatment such as the levonogestrel intrauterine system (LNG-IUS) can be effective, however there is a risk of expulsion and irregular bleedings.
In recent years, increasing attention has been paid to the study of minimally invasive or non-invasive therapies with uterine preservation such as uterine arterial embolization (UAE), radiofrequency (RF), microwave treatment and high intensity focused ultrasound (HIFU). A randomized controlled study is ongoing, comparing UAE and hysterectomy. RF ablation often requires the aid of a laparoscopic procedure, which is invasive. HIFU is currently only described in small cohorts and case-reports. Ultrasound or computer tomography guided percutaneous microwave thermal ablation is minimally invasive, has low time requirements, is easy to perform, and has been broadly used for the treatment of solid tumours in organs other than the uterus with favourable effects.
Microwave ablation of adenomyosis has been performed in China. The effect and acceptability has been high. The research team in this study has been to China to study the treatment. We have visited the clinic and studied the procedure as well as talked to patients pre- and post operatively . The equipment at Danderyd Hospital has the same output effects as the equipment in China. Danderyd Hospital has approved the method for use in uterine myomas. However, no randomized comparative study of other minimally invasive methods has been performed.
This study aims to compare the effectiveness, feasibility and acceptability of percutaneous CT- or ultrasound guided microwave ablation and uterine artery embolization for the treatment of adenomyosis in a randomized single blind study.
Recruitment and Randomization
Women fulfilling inclusion criteria and without exclusion criteria will be identified at the outpatient clinic of Danderyd Hospital. Advertisement may be placed in local newspapers or on social media (Facebook and Instagram) and relevant webpages or in gynecological clinics.
Women will be randomized after having been informed orally and in written and after having signed informed consent and after fulfilling inclusion and exclusion criteria after MRI-examination. Randomization will be in random permuted blocks of 6 at a ratio of 1:1. The randomization will be according to a computer generated randomization sequence. After patients have signed informed consent and fulfill inclusion without exclusion criteria after the initial magnetic resonance imaging they will be allocated to an intervention by consecutive opening of sealed opaque envelopes containing the randomization code.
Blinding
Patients and investigators will not be blinded. The MRI will be performed and evaluated by a blinded radiologist.
Method
Pre randomization evaluation After having signed informed consent but before randomization patients will undergo MRI of the uterus. Patients with endometriosis or a clinically significant presence of uterine fibroids (myomas\>3cm) will be excluded.
All women included in the study after MRI examination will fill in a PBAC evaluation during the menses preceding treatment. Women will fill a VNRS for maximal pain during 1 month prior to treatment. In addition a full blood panel will be evaluated.
As for uterine artery embolization no pathologist report will be performed before any treatment.
Microwave ablation Microwave ablation will be performed percutaneously or vaginally using a Covidien Emprint microwave ablation system with a 30-80 Watts effect in 14-16 gauge needle with a ceramic tip using computer tomography with fusion technique or ultrasound for adenomyosis imaging and needle guidance. After identification of the needle path with CT or peroperative ultrasound a small skin incision using a scalpel will made for the needle entry in the case of percutaneous treatment. No incision will be made if treatment is given vaginally. When needed to optimize the needle path in order not to damage adjacent organs, artificial ascites (approx 500mL Ringer-acetate) will be created using a thin syringe through the abdominal wall. The ablation zone of a 70W needle is estimated to be 4x3x3 cm after 300s or 5x4x4 cm after 600s. Patients will be given intravenous anesthesia with spontaneous breathing or general anesthesia during treatment to minimize movement during ablation.
Uterine artery embolization Embolization will be performed in conscious women with an epidural catheter or patient controlled analgesia for pain relief. A catheter will be inserted in the femoral artery to access the uterine artery during x-ray monitoring and during administration of contrast to visualize the adenomyotic tissue and its supporting arterial supply. When the supporting arterial branch has been identified polyvinyl alcohol particles are released into the bloodstream. These particles cause a thrombosis in the vessel.
Evaluation post treatment Women will estimate VNRS maximum postoperative pain day of surgery and the following 7 days. In addition, they will note how many days passed before all pain subsided, use of pain medication will be noted and period until resuming normal daily activities. The period of hospitalization will be noted.
Menstrual blood loss (PBAC) will be noted the first menstruation, menstruation number 3 and 5 post treatment. PBAC is a validated instrument for menstrual blood loss quantification. UFS-QOL is a validated instrument for women with uterine fibroids, but is commonly used also in trials regarding adenomyosis, and will be evaluated 6 months post treatment.
Follow-up visits will be after 1-2 menstruation at approximately 2 months and at 6 months post-treatment.
At follow up visit 2 months (+/-2 weeks) and 6 months (+/-2 weeks) post treatment acceptability will be assessed as overall satisfaction of treatment on a scale from 1-7 and if the woman would recommend the treatment to a friend. At the follow up visit at 6 months hemoglobin, cancer antigen 125 (CA-125), Anti-Müllerian Hormone (AMH), and prolactine (PRL) will be measured. AMH estimates the effect of the treatment on the ovarian reserve. CA-125 and PRL have been used to evaluate pathophysiological changes in adenomyosis. These will be compared to levels taken on the day of the operative procedure. A uterine biopsy will also be performed.
A new MRI scan will be performed 6 months post treatment (+/-21 days). Women will then be asked to participate in a long-term follow up (\>12 months) with evaluation of recurrence of symptoms, with clinical controls (gynecological exams and TVUS) and using PBAC and UFS-QOL yearly until retraction of consent.
Continuation of the study:
During our analysis of the initial pilot study, we noticed significant alleviation of symptoms in both treatment groups, however no significant difference between the groups (MWA vs UAE).
We however noted a significant better postoperative outcome in the MWA group:
hospitalization, return to ADL and need of analgesics postoperatively were all strongly in favor of MWA.
Also, the international research on MWA and fertility wish has proceeded during our initial study period, suggesting no significant higher risk for adverse oucomes in pregnancies after MWA.
These altered conditions made us apply for a continuation of the study to the Regional Ethical Review Board of Stockholm, with the following design:
* Prospective Interventional study of MWA treatment for symptomatic adenomyosis, n=50
* All patients receive MWA treatment and follow-up after 6 months
* Inclusion criterias remain unchanged, except for MRI no longer needed for diagnostics
* Fertility wish, cocurrent myomas and/or endometriosis no longer an exlusion criteria
Primary and secondary outcomes remain unchanged. Due to reasons listed above, we have now expanded the study period until June 2026.
Clinical significance
Adenomyosis is a benign condition but have a significant impact on the lives of women, and the condition is not well studied. Reports have suggested adenomyosis in approximately 40% of patients undergoing hysterectomy. Women with adenomyosis are much more likely to report on symptoms as dysmenhorrea, heavy menstrual bleeding, infertility and chronic pelvic pain. As hysterectomy is a highly invasive procedure with costs for women in terms of absence from work and short and long term complications, finding new minimally invasive and uterine-sparing treatments would be beneficial for affected women.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Adenomyosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
RCT with inteventional cohort continuation
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Microwave treatment
Percutaneous or vaginal application of microwave antenna with microwave treatment for adenomyosis
Group Type
EXPERIMENTAL
Microwave treatment via needle antenna
Intervention Type
PROCEDURE
Microwave treatment via needle antenna, (Emprint Covidien microwave ablation system) either percutaneous or vaginally administrated
Control
Uterine artery embolization; percutaneous application of a catheter into the femoral artery or branches thereof
Group Type
ACTIVE_COMPARATOR
Embolization of uterine artery or branches thereof (routine treatment where polyvinyl alcohol particles are released into the predefined bloodstream)
Intervention Type
PROCEDURE
Embolization via percutaneous catheter
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Microwave treatment via needle antenna
Microwave treatment via needle antenna, (Emprint Covidien microwave ablation system) either percutaneous or vaginally administrated
Intervention Type
PROCEDURE
Embolization of uterine artery or branches thereof (routine treatment where polyvinyl alcohol particles are released into the predefined bloodstream)
Embolization via percutaneous catheter
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy women aged 30-55 with symptomatic adenomyosis
* Premenopausal
* Adenomyosis diagnosted by TVUS
* Willing to comply with protocol
* Premenopausal
* Adenomyosis diagnosted by TVUS
* Willing to comply with protocol
Exclusion Criteria
* Body Mass Index \>35
* Treatment with anticoagulant/bleeding disorder
* Contraindication for UAE or general anesthesia
* Treatment with anticoagulant/bleeding disorder
* Contraindication for UAE or general anesthesia
Minimum Eligible Age
30 Years
Maximum Eligible Age
55 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karolinska Institutet
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Helena Kopp Kallner
Senior Consultant, PhD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helena Kopp Kallner, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Karolinska Institutet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Danderyd Hospital
Stockholm, , Sweden
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Sweden
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Helena Kopp Kallner, MD, PhD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Struble J, Reid S, Bedaiwy MA. Adenomyosis: A Clinical Review of a Challenging Gynecologic Condition. J Minim Invasive Gynecol. 2016 Feb 1;23(2):164-85. doi: 10.1016/j.jmig.2015.09.018. Epub 2015 Sep 30.
Reference Type
BACKGROUND
Pinzauti S, Lazzeri L, Tosti C, Centini G, Orlandini C, Luisi S, Zupi E, Exacoustos C, Petraglia F. Transvaginal sonographic features of diffuse adenomyosis in 18-30-year-old nulligravid women without endometriosis: association with symptoms. Ultrasound Obstet Gynecol. 2015 Dec;46(6):730-6. doi: 10.1002/uog.14834.
Reference Type
BACKGROUND
Dueholm M. Uterine adenomyosis and infertility, review of reproductive outcome after in vitro fertilization and surgery. Acta Obstet Gynecol Scand. 2017 Jun;96(6):715-726. doi: 10.1111/aogs.13158.
Reference Type
BACKGROUND
Li X, Liu X, Guo SW. Clinical profiles of 710 premenopausal women with adenomyosis who underwent hysterectomy. J Obstet Gynaecol Res. 2014 Feb;40(2):485-94. doi: 10.1111/jog.12211. Epub 2013 Oct 22.
Reference Type
BACKGROUND
Van den Bosch T, Van Schoubroeck D. Ultrasound diagnosis of endometriosis and adenomyosis: State of the art. Best Pract Res Clin Obstet Gynaecol. 2018 Aug;51:16-24. doi: 10.1016/j.bpobgyn.2018.01.013. Epub 2018 Feb 14.
Reference Type
BACKGROUND
Sheng J, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009 Mar;79(3):189-93. doi: 10.1016/j.contraception.2008.11.004. Epub 2008 Dec 11.
Reference Type
BACKGROUND
de Bruijn AM, Smink M, Lohle PNM, Huirne JAF, Twisk JWR, Wong C, Schoonmade L, Hehenkamp WJK. Uterine Artery Embolization for the Treatment of Adenomyosis: A Systematic Review and Meta-Analysis. J Vasc Interv Radiol. 2017 Dec;28(12):1629-1642.e1. doi: 10.1016/j.jvir.2017.07.034. Epub 2017 Oct 9.
Reference Type
BACKGROUND
de Bruijn AM, Lohle PN, Huirne JA, de Vries J, Twisk M; QUESTA-Trial Group; Hehenkamp WJ. Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Adenomyosis: Protocol for the Randomized QUESTA Trial. JMIR Res Protoc. 2018 Mar 1;7(3):e47. doi: 10.2196/resprot.8512.
Reference Type
BACKGROUND
Guo Q, Xu F, Ding Z, Li P, Wang X, Gao B. High intensity focused ultrasound treatment of adenomyosis: a comparative study. Int J Hyperthermia. 2018;35(1):505-509. doi: 10.1080/02656736.2018.1509238. Epub 2018 Oct 11.
Reference Type
BACKGROUND
Hai N, Zhang J, Xu R, Han ZY, Liu FY. Percutaneous microwave ablation with artificial ascites for symptomatic uterine adenomyosis: initial experience. Int J Hyperthermia. 2017 Sep;33(6):646-652. doi: 10.1080/02656736.2017.1285444. Epub 2017 Feb 15.
Reference Type
BACKGROUND
Xu RF, Zhang J, Han ZY, Zhang BS, Liu H, Li XM, Ge HL, Dong XJ. Variables associated with vaginal discharge after ultrasound-guided percutaneous microwave ablation for adenomyosis. Int J Hyperthermia. 2016 Aug;32(5):504-10. doi: 10.3109/02656736.2016.1150523. Epub 2016 Apr 18.
Reference Type
BACKGROUND
Yang Y, Zhang J, Han ZY, Ma X, Hao YL, Xu CT, Xu RF, Zhang BS. Ultrasound-guided percutaneous microwave ablation for adenomyosis: efficacy of treatment and effect on ovarian function. Sci Rep. 2015 May 5;5:10034. doi: 10.1038/srep10034.
Reference Type
BACKGROUND
Xia M, Jing Z, Zhi-Yu H, Jian-Ming C, Hong-Yu Z, Rui-Fang X, Yu Y, Yan-Li H, Bao-Wei D. Feasibility study on energy prediction of microwave ablation upon uterine adenomyosis and leiomyomas by MRI. Br J Radiol. 2014 Aug;87(1040):20130770. doi: 10.1259/bjr.20130770. Epub 2014 Jun 20.
Reference Type
BACKGROUND
Zhang J, Han ZY, Feng L, Wang F, Hu DM, Wen B, Li ZC. [Ultrasound-guided percutaneous microwave ablation in the treatment of diffuse adenomyosis]. Zhonghua Yi Xue Za Zhi. 2011 Oct 25;91(39):2749-52. Chinese.
Reference Type
BACKGROUND
Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. BJOG. 2000 Mar;107(3):320-2. doi: 10.1111/j.1471-0528.2000.tb13225.x.
Reference Type
BACKGROUND
Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol. 2002 Feb;99(2):290-300. doi: 10.1016/s0029-7844(01)01702-1.
Reference Type
BACKGROUND
Harding G, Coyne KS, Thompson CL, Spies JB. The responsiveness of the uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL). Health Qual Life Outcomes. 2008 Nov 12;6:99. doi: 10.1186/1477-7525-6-99.
Reference Type
BACKGROUND
Coyne KS, Margolis MK, Murphy J, Spies J. Validation of the UFS-QOL-hysterectomy questionnaire: modifying an existing measure for comparative effectiveness research. Value Health. 2012 Jul-Aug;15(5):674-9. doi: 10.1016/j.jval.2012.03.1387. Epub 2012 Jun 8.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ADENOMIC1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Clinical Trial of Uterine Artery Embolization for Uterine Leiomyoma
NCT00821275
UNKNOWN
PHASE2/PHASE3
Endometrial Ablation With Non-hysteroscopic Methods
NCT01173965
COMPLETED
PHASE4
Uterine Artery Embolization(UAE) Versus High-Intensity-Focused-Ultrasound(HIFU) for Treatment of Uterine Fibroids
NCT01834703
TERMINATED
NA
Satisfaction of Patients With Trans-Arterial Radial Access: Quality of Life in Uterine Fibroid Embolization Trial
NCT03021720
COMPLETED
NA
The Effect of Adenomoyosis on Pregnancy Outcomes
NCT04894292
UNKNOWN
Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis
NCT03520439
COMPLETED
PHASE2/PHASE3
Post-Operative Pain Management in Patients Undergoing Uterine Artery Embolisation for Symptomatic Leiomyomata
NCT00163930
UNKNOWN
Use of Dexamethasone in Uterine Artery Embolization
NCT02056717
COMPLETED
NA
What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography
NCT01992718
COMPLETED
EARLY_PHASE1
Efficacy of Cryoablation of Abdominal Wall Endometriosis
NCT03627676
UNKNOWN
NA
Fertility After Myomectomy Versus Uterine Artery Embolization for Symptomatic Uterine Fibroids
NCT02577055
COMPLETED
NA
Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis
NCT03027648
COMPLETED
NA
Study of the Prevalence of Endometriosis and Adenomyosis
NCT06211569
RECRUITING
Electroacupuncture for Dysmenorrhea Secondary to Adenomyosis
NCT06364592
RECRUITING
NA
Histologic Comparison of Ablative Techniques for Endometriosis
NCT06414083
RECRUITING
NA
Assessment of Ovarian Reserve After Laparoscopic Cystectomy Versus Aspiration/Electrocoagulation in the Treatment of Ovarian Endometrioma
NCT04151173
UNKNOWN
NA
Clinical and Molecular Study of Endometriosis and Adenomyosis
NCT04481321
RECRUITING
Study to Evaluate the Safety and Effectiveness of MRgFUS Compared With Myomectomy for the Treatment of Uterine Fibroids
NCT01328067
WITHDRAWN
NA
Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI
NCT04665414
COMPLETED
Ovarian Endometrioma Ablation Using Plasma Energy Versus Cystectomy
NCT01596985
UNKNOWN
PHASE2
Fertility After Uterine Artery Embolization
NCT05271981
UNKNOWN
Comparison Study in the Treatment of Uterine Fibroids Uterine Fibroid Embolization Using BeadBlock™ Embolic Agent
NCT00361036
COMPLETED
PHASE1
Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis
NCT03325868
WITHDRAWN
PHASE4
Levonorgestrel Intrauterine System and Adenomyosis
NCT03104309
COMPLETED
NA
Efficacy of Estrogen-intrauterine Stent System After Intrauterine Adhesiolysis
NCT04972032
UNKNOWN
NA